Type of evidence supporting ACC/AHA and ESC clinical practice guidelines for acute coronary syndrome

Sodium–glucose cotransporter 2 inhibitors in acute and chronic coronary syndrome with and without heart failure

“…90 days before), dedicated post‐MI trials of these drugs have led to its implementation in ACS patients. Hence, recommendations of the American and European guidelines for the management of ACS are supported by a mixed of RCTs conducted in patients with HF (and without ACS) and in patients with ACS (with and without HF) 9,10 . However, not all therapies with proven efficacy in patients with chronic HFrEF have demonstrated benefit in post‐MI patients.…”